Literature DB >> 23325294

Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.

Edward L Jones1, Teresa S Jones, Nathan W Pearlman, Dexiang Gao, Robert Stovall, Csaba Gajdos, Nicole Kounalakis, Rene Gonzalez, Karl D Lewis, William A Robinson, Martin D McCarter.   

Abstract

OBJECTIVE: To analyze the predictors and patterns of recurrence of melanoma in patients with a negative sentinel lymph node biopsy result.
DESIGN: Retrospective chart review of a prospectively created database of patients with cutaneous melanoma. SETTING Tertiary university hospital. PATIENTS: A total of 515 patients with melanoma underwent a sentinel lymph node biopsy without evidence of metastatic disease between 1996 and 2008. MAIN OUTCOME MEASURES: Time to recurrence and overall survival.
RESULTS: Of 515 patients, 83 (16%) had a recurrence of melanoma at a median of 23 months during a median follow-up of 61 months (range, 1-154 months). Of these 83 patients, 21 had melanoma that metastasized in the studied nodal basin for an in-basin false-negative rate of 4.0%. Patients with recurrence had deeper primary lesions (mean thickness, 2.7 vs 1.8 mm; P < .01) that were more likely to be ulcerated (32.5% vs 13.5%; P < .001) than those without recurrence. The primary melanoma of patients with recurrence was more likely to be located in the head and neck region compared with all other locations combined (31.8% vs 11.7%; P < .001). Median survival following a recurrence was 21 months (range, 1-106 months). Favorable characteristics associated with lower risk of recurrence included younger age at diagnosis (mean, 49 vs 57 years) and female sex (9% vs 21% for males; P < .001).
CONCLUSION: Overall, recurrence of melanoma (16%) after a negative sentinel lymph node biopsy result was similar to that in previously reported studies with an in-basin false-negative rate of 4.0%. Lesions of the head and neck, the presence of ulceration, increasing Breslow thickness, older age, and male sex are associated with increased risk of recurrence, despite a negative sentinel lymph node biopsy result.

Entities:  

Mesh:

Year:  2013        PMID: 23325294      PMCID: PMC3856253          DOI: 10.1001/jamasurg.2013.1335

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  23 in total

1.  Patterns of early recurrence after sentinel lymph node biopsy for melanoma.

Authors:  Celia Chao; Sandra L Wong; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; Patricia B Cerrito; Michael J Edwards; Kelly M McMasters
Journal:  Am J Surg       Date:  2002-12       Impact factor: 2.565

2.  The definition of the sentinel lymph node in melanoma based on radioactive counts.

Authors:  Grant W Carlson; Douglas R Murray; Vinod Thourani; Andrea Hestley; Cynthia Cohen
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

3.  Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.

Authors:  Kathryn Spanknebel; Daniel G Coit; Samuel C Bieligk; Mithat Gonen; Juan Rosai; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2005-03       Impact factor: 6.394

4.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.

Authors:  J E Gershenwald; W Thompson; P F Mansfield; J E Lee; M I Colome; C H Tseng; J J Lee; C M Balch; D S Reintgen; M I Ross
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence.

Authors:  B M Clary; M S Brady; J J Lewis; D G Coit
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

8.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  Lessons learned from the Sunbelt Melanoma Trial.

Authors:  Kelly M McMasters; R Dirk Noyes; Douglas S Reintgen; James S Goydos; Peter D Beitsch; B Scott Davidson; Jeffrey J Sussman; Jeffrey E Gershenwald; Merrick I Ross
Journal:  J Surg Oncol       Date:  2004-07-01       Impact factor: 3.454

10.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma.

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Surgery       Date:  1979-08       Impact factor: 3.982

View more
  19 in total

1.  Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases.

Authors:  Yoshitsugu Shibayama; Shinichi Imafuku; Akira Takahashi; Juichiro Nakayama
Journal:  Int J Clin Oncol       Date:  2014-04-01       Impact factor: 3.402

Review 2.  Current treatment of locoregional recurrence of melanoma.

Authors:  Malcolm Hart Squires; Keith A Delman
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 3.  Analysis of melanoma recurrence following a negative sentinel lymph node biopsy.

Authors:  Maggie Hodges; Edward Jones; Teresa Jones; Nathan Pearlman; Csaba Gajdos; Nicole Kounalakis; Martin McCarter
Journal:  Melanoma Manag       Date:  2015-08-10

4.  Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Authors:  Laura J Gardner; Morgan Ward; Robert H I Andtbacka; Kenneth M Boucher; Glen M Bowen; Tawnya L Bowles; Adam L Cohen; Kenneth Grossmann; Ying J Hitchcock; Sheri L Holmen; John Hyngstrom; Hung Khong; Martin McMahon; Marcus M Monroe; Carolyn B Ross; Gita Suneja; David Wada; Douglas Grossman
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

5.  Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.

Authors:  Monika Vishnoi; Debasish Boral; Haowen Liu; Marc L Sprouse; Wei Yin; Debalina Goswami-Sewell; Michael T Tetzlaff; Michael A Davies; Isabella C Glitza Oliva; Dario Marchetti
Journal:  Cancer Res       Date:  2018-07-19       Impact factor: 12.701

6.  Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma.

Authors:  Richard J Straker; Michael J Carr; Andrew J Sinnamon; Adrienne B Shannon; James Sun; Karenia Landa; Kirsten M Baecher; Christian Wood; Kevin Lynch; Harrison G Bartels; Robyn Panchaud; Michael C Lowe; Craig L Slingluff; Mark J Jameson; Kenneth Tsai; Mark B Faries; Georgia M Beasley; Vernon Sondak; Giorgos C Karakousis; Jonathan S Zager; John T Miura
Journal:  Ann Surg Oncol       Date:  2021-04-22       Impact factor: 5.344

7.  Predictors and Survival Impact of False-Negative Sentinel Nodes in Melanoma.

Authors:  David Y Lee; Kelly T Huynh; Annabelle Teng; Briana J Lau; Sarah Vitug; Ji-Hey Lee; Stacey L Stern; Leland J Foshag; Mark B Faries
Journal:  Ann Surg Oncol       Date:  2015-11-19       Impact factor: 5.344

8.  Hypopigmented atypical Spitzoid neoplasms (atypical Spitz nevi, atypical Spitz tumors, Spitzoid melanoma): a clinicopathological update.

Authors:  Gerardo Ferrara; Stefano Cavicchini; Maria Teresa Corradin
Journal:  Dermatol Pract Concept       Date:  2015-01-30

9.  Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety.

Authors:  John E Hanks; Kevin J Kovatch; S Ahmed Ali; Emily Roberts; Alison B Durham; Joshua D Smith; Carol R Bradford; Kelly M Malloy; Philip S Boonstra; Christopher D Lao; Scott A McLean
Journal:  Otolaryngol Head Neck Surg       Date:  2020-02-11       Impact factor: 3.497

10.  Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients.

Authors:  Lutz Kretschmer; Hans Peter Bertsch; Antonia Zapf; Christina Mitteldorf; Imke Satzger; Kai-Martin Thoms; Bernward Völker; Michael Peter Schön; Ralf Gutzmer; Hans Starz
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.